UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.
December 13, 2010
November 01, 2010
Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive decline after surgery, according to a new study led by researchers at UCSF and colleagues at Imperial College London.
November 01, 2010
Rapamycin, an FDA-approved drug prescribed to prevent the rejection of transplanted organs, has been shown for the first time to decrease excessive alcohol consumption, binge drinking, and alcohol-seeking behavior in rodents.
October 22, 2010
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
September 21, 2010
An inexpensive, hundred-year-old therapy for pain – aspirin – is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center.
September 07, 2010
UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual’s response to medication and to strengthen a global network of researchers involved in these efforts.
July 15, 2010
A diabetes-care program designed by clinical pharmacy faculty in the UCSF School of Pharmacy Center for Self-Care has just launched in Northern California as a service for members of the California Public Employees Retirement System (CalPERS) with Blue Shield health coverage.
February 19, 2010
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
January 25, 2010
Some of the leading scientists in bioengineering, nanotechnology and pharmaco-genomics will gather on Tuesday, January 26, 2010 to discuss how to harness the tools of these emerging fields to develop new diagnostics and treatments for complex diseases.